A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 05 Nov 2018 Planned End Date changed from 1 Apr 2019 to 1 Oct 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated